JohnsonAndJohnson

J&J's $8.2 Billion Talc Settlement Faces Crucial January Assessment

2 months ago

In a pivotal development for Johnson & Johnson, the company’s monumental $8.2 billion settlement over claims related to its talc-based products is set to undergo a significant evaluation in January. This legal maneuver comes on the heels of extensive allegations that J&J’s talcum powder has been linked to cancer, resulting in a slew of lawsuits against the healthcare giant.

J&J Talc Settlement Under Fire: Allegations of Vote Buying Surface

2 months ago

In a dramatic turn of events surrounding Johnson & Johnson’s (J&J) ongoing talc litigation, certain holdouts in a massive bankruptcy settlement have leveled serious accusations against the pharmaceutical giant. They claim that J&J has engaged in unethical practices aimed at swaying votes in favor of its proposed $8.9 billion settlement aimed at resolving thousands of claims related to its talc-based products.

Johnson & Johnson Surprises with Profit Surge Amid Strong Darzalex Sales

2 months ago

In a remarkable performance that outshined analysts' expectations, Johnson & Johnson reported a significant boost in profits driven largely by the impressive sales of its cancer treatment drug, Darzalex. The healthcare giant has proven its resilience amid a competitive market landscape, showcasing not only strong product demand but also strategic management of its resources.

Johnson & Johnson's Talc Bankruptcy Case to Remain in Texas, Increasing Chances for Settlement

2 months ago

In a pivotal ruling that could reshape the landscape for thousands of litigants, a Texas bankruptcy judge has decided to keep Johnson & Johnson’s contentious talc bankruptcy case within the state. This decision, seen as a significant victory for the pharmaceutical giant, could boost the likelihood of a resolution for numerous claims alleging that its talcum powder caused cancers, including ovarian cancer.